| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(2 years from now) | |
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(8 years from now) | |
| US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(9 years from now) | |
| US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
| US11311500 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(11 years from now) | |
Spravato is owned by Janssen Pharms.
Spravato contains Esketamine Hydrochloride.
Spravato has a total of 6 drug patents out of which 0 drug patents have expired.
Spravato was authorised for market use on 05 March, 2019.
Spravato is available in spray;nasal dosage forms.
Spravato can be used as treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant, treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant, treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks, treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant, treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant.
The generics of Spravato are possible to be released after 10 September, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Mar 05, 2024 |
| New Indication(I-840) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketami...
Dosage: SPRAY;NASAL
SPRAVATO family patents
